Lumexa Imaging (NASDAQ:LMRI) Rating Increased to Strong-Buy at Raymond James Financial

Raymond James Financial upgraded shares of Lumexa Imaging (NASDAQ:LMRI) from an outperform rating to a strong-buy rating in a research note issued to investors on Monday morning, Marketbeat.com reports. The firm currently has $23.00 price objective on the stock.

Lumexa Imaging Stock Performance

Shares of LMRI opened at $11.55 on Monday. Lumexa Imaging has a 52 week low of $9.97 and a 52 week high of $19.45.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Lumexa Imaging stock. Geode Capital Management LLC acquired a new stake in Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 83,675 shares of the company’s stock, valued at approximately $1,548,000. Geode Capital Management LLC owned approximately 0.09% of Lumexa Imaging at the end of the most recent reporting period.

Lumexa Imaging Company Profile

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).